In this section

Clinical trials

Active clinical trials

Clinical Trials - Diseases by specialty group


Leukemia 11

    Protocol ID
  • Associated disease
    Title
    A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
    A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients with Relapsed and Refractory Acute Myeloid Leukemia
    IIT-MOSKOP-MABD
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Chronic Mylegenous Leukemia (CML)
  • Myeloma/Myelodysplastic Syndrome (MDS)
  • Other Leukemia
    Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation with Alpha/Beta T-Cell and B-Cell Depletion for Patients with Hematologic Malignancies with Targeted ATG Dosing Pilot Study, IDE 13641
    IIT-Steineck-CARTPLUS: Chimeric Antigen Receptor T-cell Pediatrics Living with Uncertainty (CAR T-PLUS) Intervention Proof of Concept Study
    MAGIC-LRPEDS
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Other Leukemia
    Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD
    A Phase II Pilot Study of Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults with High-Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study (EXCEL Trial)
    TACL-T2020-006
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Myeloma/Myelodysplastic Syndrome (MDS)
  • Other Leukemia
    A Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
    Evaluation of Long-term Safety in Paediatric Patients With B-precursor Acute Lymphoblastic Leukemia (ALL) who Have Been Treated With Either Blinatumomab or Chemotherapy, Followed by Transplantation
    COG-AALL1732
  • Acute Lymphoblastic Leukemia (ALL)
  • Other Leukemia
    A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
    COG-ACCL1931
  • Acute Lymphoblastic Leukemia (ALL)
  • Other Leukemia
    A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
    Communication in the Early Pediatric Cancer Treatment Period
Contact us

For more information about cancer and blood disorders clinical trials, email us or call

(414) 955-4727

Get a second opinion

It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.

Why participate in clinical trials?

Michael Burke, MD

"The steady improvement in survival for children with cancer is a direct result of their enrollment onto clinical trials; without which we would remain decades behind in terms of scientific advances in pediatric cancer." ~Michael J. Burke, MD